S100P Interacts with p53 while Pentamidine Inhibits This Interaction.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• S100P protein binds to p53, potentially inactivating its tumor-suppressive functions.
• The interaction between S100P and p53 is a potential target for cancer therapy.

Purpose of the Study:

• To investigate the molecular interaction between S100P and p53.
• To evaluate pentamidine as an antagonist of the S100P-p53 complex.
• To assess the therapeutic potential of targeting this interaction.

Main Methods:

• ¹H-¹⁵N HSQC experiments to study protein interactions.
• Molecular modeling to visualize binding sites.
• Cell proliferation assays on breast cancer cells (ZR-75-1).

Main Results:

• Pentamidine disrupts the S100P-p53 complex by competing for the same binding site.
• Pentamidine treatment reduces breast cancer cell proliferation.
• Pentamidine increases levels of p53 and p21 proteins, indicating pathway re-activation.

Conclusions:

• Pentamidine effectively antagonizes the S100P-p53 interaction.
• Targeting the S100P-p53 association with pentamidine shows promise for cancer therapy.
• This approach offers a novel strategy to inhibit cancer progression by re-activating the p53-21 pathway.